Entering text into the input field will update the search result below

Vanda Pharma prevails in Fanapt patent challenge

  • The U.S. Supreme Court has denied the petition for a writ of certiorari (orders a lower court to deliver its record in a case so the higher court may review it) from a subsidiary of Hikma Pharmaceuticals related to U.S. Patent No. 8,586,610 covering Vanda Pharmaceuticals' (VNDA -5.2%) Fanapt (iloperidone) tablets.
  • The denial means that the patent will remain in effect through November 2, 2027 (unless successfully challenged beforehand).

Recommended For You

About VNDA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
VNDA--
Vanda Pharmaceuticals Inc.